{"id":52924,"date":"2026-01-05T23:03:39","date_gmt":"2026-01-05T15:03:39","guid":{"rendered":"https:\/\/flcube.com\/?p=52924"},"modified":"2026-01-05T23:03:40","modified_gmt":"2026-01-05T15:03:40","slug":"insilico-medicine-partners-with-servier-on-888-million-ai-oncology-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=52924","title":{"rendered":"Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal"},"content":{"rendered":"\n<p><strong>Insilico Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3696:HKG\">HKG: 3696<\/a>) announced a <strong>multi\u2011year R&amp;D collaboration<\/strong> with <strong>Servier<\/strong> to identify and develop novel therapeutics for challenging oncology targets using Insilico\u2019s proprietary <strong>Pharma.AI<\/strong> platform. The alliance, valued at up to <strong>USD\u202f888\u202fmillion<\/strong>, includes <strong>USD\u202f32\u202fmillion<\/strong> in upfront and near\u2011term payments, with Servier leading clinical validation and worldwide commercialization.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-alliance-overview\">Strategic Alliance Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Insilico Medicine (AI platform), Servier (pharma partner)<\/td><\/tr><tr><td><strong>Collaboration Type<\/strong><\/td><td>Multi\u2011year R&amp;D partnership<\/td><\/tr><tr><td><strong>Therapeutic Area<\/strong><\/td><td>Oncology (challenging targets)<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Insilico\u2019s Pharma.AI platform<\/td><\/tr><tr><td><strong>Financial Value<\/strong><\/td><td>Up to <strong>USD\u202f888\u202fmillion<\/strong><\/td><\/tr><tr><td><strong>Upfront\/Near\u2011Term Payments<\/strong><\/td><td><strong>USD\u202f32\u202fmillion<\/strong><\/td><\/tr><tr><td><strong>Cost Structure<\/strong><\/td><td>Servier shares in R&amp;D costs<\/td><\/tr><tr><td><strong>Post\u2011Discovery Role<\/strong><\/td><td>Servier leads clinical validation, regulatory, and global commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-pharma-ai-platform\">Technology Profile: Pharma.AI Platform<\/h2>\n\n\n\n<p><strong>Insilico\u2019s Proprietary AI System<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Identification<\/strong>: Uses deep learning to identify novel oncology targets with high disease relevance<\/li>\n\n\n\n<li><strong>Molecule Generation<\/strong>:AI-driven de novo design of drug candidates with optimized potency and safety<\/li>\n\n\n\n<li><strong>Clinical Prediction<\/strong>:Predictive models for clinical trial outcomes to de-risk development<\/li>\n<\/ul>\n\n\n\n<p><strong>Competitive Edge<\/strong>: Accelerates discovery from <strong>3-5 years to 12-18 months<\/strong>, reducing preclinical costs by <strong>40-50%<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-structure-amp-milestones\">Financial Structure &amp; Milestones<\/h2>\n\n\n\n<p><strong>Payment Timeline<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upfront<\/strong>: USD\u202f32\u202fmillion (covers initial R&amp;D activities)<\/li>\n\n\n\n<li><strong>Development Milestones<\/strong>: Up to <strong>USD\u202f856\u202fmillion<\/strong> tied to candidate advancement and clinical progress<\/li>\n\n\n\n<li><strong>Royalties<\/strong>: Tiered mid\u2011single\u2011digit to low\u2011double\u2011digit royalties on net sales (if applicable)<\/li>\n<\/ul>\n\n\n\n<p><strong>Risk Sharing<\/strong>: Servier\u2019s participation in R&amp;D costs aligns incentives and reduces Insilico\u2019s capital burden.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-ai-in-oncology-drug-discovery\">Market Context: AI in Oncology Drug Discovery<\/h2>\n\n\n\n<p><strong>Global AI Drug Discovery Market<\/strong>: <strong>$2.5\u202fbillion<\/strong> (2025), projected to reach <strong>$10\u202fbillion<\/strong> by 2030.<\/p>\n\n\n\n<p><strong>Servier\u2019s Strategic Need<\/strong>: The French pharma company seeks to <strong>replenish its oncology pipeline<\/strong> after <strong>Lonsurf<\/strong> generic competition and <strong>aspadol<\/strong> setbacks.<\/p>\n\n\n\n<p><strong>Insilico\u2019s Validation<\/strong>: This partnership <strong>validates Pharma.AI\u2019s<\/strong> capability to attract <strong>top\u2011tier pharma partners<\/strong>, following similar deals with <strong>Fosun Pharma<\/strong> and <strong>EQRx<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-pathway\">Development Pathway<\/h2>\n\n\n\n<p><strong>Candidate Selection<\/strong>: Insilico will advance candidates meeting <strong>predefined scientific and development criteria<\/strong> (potency, selectivity, ADME).<\/p>\n\n\n\n<p><strong>Servier\u2019s Role<\/strong>: Upon candidate identification, Servier assumes <strong>full responsibility<\/strong> for:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>IND\u2011enabling studies<\/li>\n\n\n\n<li>Clinical trial execution<\/li>\n\n\n\n<li>Regulatory submissions (FDA, EMA, NMPA)<\/li>\n\n\n\n<li>Global commercialization<\/li>\n<\/ul>\n\n\n\n<p><strong>Timeline<\/strong>: First candidate expected to enter <strong>Phase\u202fI in 2027<\/strong>, with <strong>2\u20113 additional candidates<\/strong> nominated annually.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Insilico\u2019s R&amp;D timeline, milestone achievements, and Servier\u2019s commercialization plans. Actual results may differ materially due to clinical trial outcomes, competitive dynamics, and regulatory acceptance of AI\u2011discovered drugs.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696) announced a multi\u2011year R&amp;D collaboration with Servier to identify and develop&#8230;<\/p>\n","protected":false},"author":1,"featured_media":52928,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,6],"tags":[99,4514,164,1496],"class_list":["post-52924","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-rd","tag-ai","tag-hkg-3696","tag-insilico-medicine","tag-servier-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696) announced a multi\u2011year R&amp;D collaboration with Servier to identify and develop novel therapeutics for challenging oncology targets using Insilico\u2019s proprietary Pharma.AI platform. The alliance, valued at up to USD\u202f888\u202fmillion, includes USD\u202f32\u202fmillion in upfront and near\u2011term payments, with Servier leading clinical validation and worldwide commercialization.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=52924\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696) announced a multi\u2011year R&amp;D collaboration with Servier to identify and develop novel therapeutics for challenging oncology targets using Insilico\u2019s proprietary Pharma.AI platform. The alliance, valued at up to USD\u202f888\u202fmillion, includes USD\u202f32\u202fmillion in upfront and near\u2011term payments, with Servier leading clinical validation and worldwide commercialization.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=52924\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-05T15:03:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-05T15:03:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0508.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52924#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52924\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal\",\"datePublished\":\"2026-01-05T15:03:39+00:00\",\"dateModified\":\"2026-01-05T15:03:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52924\"},\"wordCount\":418,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52924#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0508.webp\",\"keywords\":[\"AI\",\"HKG: 3696\",\"Insilico Medicine\",\"Servier Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\",\"R&amp;D\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52924#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52924\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=52924\",\"name\":\"Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52924#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52924#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0508.webp\",\"datePublished\":\"2026-01-05T15:03:39+00:00\",\"dateModified\":\"2026-01-05T15:03:40+00:00\",\"description\":\"Insilico Medicine (HKG: 3696) announced a multi\u2011year R&D collaboration with Servier to identify and develop novel therapeutics for challenging oncology targets using Insilico\u2019s proprietary Pharma.AI platform. The alliance, valued at up to USD\u202f888\u202fmillion, includes USD\u202f32\u202fmillion in upfront and near\u2011term payments, with Servier leading clinical validation and worldwide commercialization.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52924#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=52924\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52924#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0508.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0508.webp\",\"width\":1080,\"height\":608,\"caption\":\"Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=52924#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696) announced a multi\u2011year R&D collaboration with Servier to identify and develop novel therapeutics for challenging oncology targets using Insilico\u2019s proprietary Pharma.AI platform. The alliance, valued at up to USD\u202f888\u202fmillion, includes USD\u202f32\u202fmillion in upfront and near\u2011term payments, with Servier leading clinical validation and worldwide commercialization.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=52924","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal","og_description":"Insilico Medicine (HKG: 3696) announced a multi\u2011year R&D collaboration with Servier to identify and develop novel therapeutics for challenging oncology targets using Insilico\u2019s proprietary Pharma.AI platform. The alliance, valued at up to USD\u202f888\u202fmillion, includes USD\u202f32\u202fmillion in upfront and near\u2011term payments, with Servier leading clinical validation and worldwide commercialization.","og_url":"https:\/\/flcube.com\/?p=52924","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-05T15:03:39+00:00","article_modified_time":"2026-01-05T15:03:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0508.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=52924#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=52924"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal","datePublished":"2026-01-05T15:03:39+00:00","dateModified":"2026-01-05T15:03:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=52924"},"wordCount":418,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=52924#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0508.webp","keywords":["AI","HKG: 3696","Insilico Medicine","Servier Pharmaceuticals"],"articleSection":["Company","Deals","R&amp;D"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=52924#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=52924","url":"https:\/\/flcube.com\/?p=52924","name":"Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=52924#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=52924#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0508.webp","datePublished":"2026-01-05T15:03:39+00:00","dateModified":"2026-01-05T15:03:40+00:00","description":"Insilico Medicine (HKG: 3696) announced a multi\u2011year R&D collaboration with Servier to identify and develop novel therapeutics for challenging oncology targets using Insilico\u2019s proprietary Pharma.AI platform. The alliance, valued at up to USD\u202f888\u202fmillion, includes USD\u202f32\u202fmillion in upfront and near\u2011term payments, with Servier leading clinical validation and worldwide commercialization.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=52924#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=52924"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=52924#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0508.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0508.webp","width":1080,"height":608,"caption":"Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=52924#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0508.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=52924"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52924\/revisions"}],"predecessor-version":[{"id":52929,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/52924\/revisions\/52929"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/52928"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=52924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=52924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=52924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}